Last updated: August 7, 2026
Spironolactone/hydrochlorothiazide is a mature, generic fixed-dose combination with limited patent or exclusivity value. The product is marketed primarily as generic tablets in the United States and has no biosimilar pathway. Revenue is driven by prescription volume, pharmacy-channel pricing, and supply continuity rather than brand premiums or new indications. Public company filings generally do not disclose sales for this combination separately.
What is spironolactone/hydrochlorothiazide used for?
Spironolactone/hydrochlorothiazide combines an aldosterone antagonist with a thiazide diuretic. The combination provides potassium-sparing and potassium-losing effects that can partially offset each other.
The FDA-approved product, historically marketed as Aldactazide, is used for:
- Edema associated with congestive heart failure
- Cirrhosis of the liver
- Nephrotic syndrome
- Essential hypertension when combination therapy is appropriate
- Conditions involving secondary hyperaldosteronism
The product is available in tablet strengths that historically included 25 mg/25 mg, 50 mg/50 mg, and 100 mg/100 mg of spironolactone/hydrochlorothiazide, respectively. Actual commercial availability varies by manufacturer and strength.[1]
The combination is less central to current hypertension treatment than separate spironolactone and hydrochlorothiazide products or newer fixed-dose antihypertensive combinations. Clinicians often prefer separate components because they can independently adjust potassium balance, diuretic intensity, and aldosterone blockade.
How large is the spironolactone/hydrochlorothiazide market?
The U.S. market is a small, mature segment within the broader oral diuretic market. No major manufacturer publicly reports global or U.S. revenue for spironolactone/hydrochlorothiazide as a standalone product.
Market characteristics include:
| Market factor |
Assessment |
| Product type |
Small-molecule fixed-dose combination |
| Regulatory status |
Generic prescription product |
| Primary dosage form |
Oral tablet |
| Branded product |
Aldactazide, with limited commercial relevance |
| Patent value |
Historical protection expired |
| Biosimilar exposure |
None |
| Generic competition |
High |
| Pricing power |
Low |
| Sales reporting |
Usually aggregated with broader generic portfolios |
| Main demand drivers |
Edema, hypertension, heart failure, cirrhosis |
| Main substitutes |
Separate spironolactone and hydrochlorothiazide; other diuretic combinations |
| Commercial growth profile |
Stable to declining nominal revenue, with episodic supply-driven price movements |
Spironolactone itself has a much larger clinical and commercial market than the fixed-dose combination. Its use has expanded in heart failure, resistant hypertension, primary aldosteronism, acne, hirsutism, and other endocrine-related conditions. That broader demand does not automatically translate into equivalent growth for the combination because many patients receive spironolactone as a standalone drug.[2]
What is the financial trajectory for spironolactone/hydrochlorothiazide?
The product’s financial trajectory is consistent with a late-life generic medicine:
- Brand revenue declined after generic entry.
- Multiple manufacturers compressed average selling prices.
- Unit demand remained linked to chronic cardiovascular and edema-related treatment.
- Revenue became sensitive to manufacturing disruptions and supplier exits.
- Profitability shifted from brand economics to high-volume, low-margin generic supply.
The combination has little prospect of generating premium revenue through product differentiation. Financial performance depends on:
- Manufacturing scale
- API sourcing
- Contracting with wholesalers and pharmacy benefit managers
- Product availability
- Ability to maintain multiple strengths
- Avoidance of manufacturing or quality-related disruption
- Geographic coverage
A generic manufacturer with an efficient tableting and packaging platform can earn recurring revenue from the product, but the combination is unlikely to become a material growth driver unless competitors withdraw or supply constraints create temporary pricing increases.
Revenue exposure for manufacturers
For large generic companies, spironolactone/hydrochlorothiazide is more likely to be part of a portfolio of mature cardiovascular products than a separately managed commercial asset. For smaller suppliers, the product can provide niche revenue if they maintain reliable supply in underrepresented strengths.
The combination can have strategic value where a manufacturer already produces:
- Spironolactone tablets
- Hydrochlorothiazide tablets
- Other cardiovascular generics
- Contract-manufactured oral solid doses
- Products distributed through institutional or government channels
The financial upside is limited by substitution with the two component drugs. If the fixed-dose product experiences a price increase, pharmacies and prescribers can often shift to separate spironolactone and hydrochlorothiazide prescriptions.
What patents protect spironolactone/hydrochlorothiazide?
The principal product protection for spironolactone/hydrochlorothiazide is expired. The original Aldactazide product was approved decades ago, and the relevant composition, formulation, and use protections are outside their enforceable patent terms.
The current commercial estate is therefore based on FDA approval and manufacturing capability rather than blocking patent rights.
| IP category |
Current commercial significance |
| Original composition patents |
Expired |
| Original product patents |
Expired |
| Fixed-dose formulation patents |
Historical protection expired |
| Method-of-use patents |
No meaningful blocking estate identified for ordinary generic use |
| Manufacturing patents |
Potentially relevant only if a supplier uses a proprietary process |
| Trade secrets |
Possible manufacturing and quality-control value |
| Trademarks |
Limited value relative to generic supply |
| Data exclusivity |
Expired |
A manufacturer could still obtain a patent on a genuinely novel formulation, delivery system, manufacturing process, or therapeutic use. Such a patent would not restore broad exclusivity over conventional spironolactone/hydrochlorothiazide tablets.
What is the FDA Orange Book status?
The original Aldactazide approval is associated with FDA NDA 012151. The product has a long regulatory history, and commercial supply is primarily represented by generic ANDA applicants rather than a protected branded product.[3]
The practical Orange Book position is:
- The product is a legacy small-molecule combination.
- Its original exclusivity period has expired.
- Generic approval does not depend on current branded market protection.
- Any remaining Orange Book-listed patent would need to be reviewed at the current product and NDA level before a launch or litigation decision.
- The commercial risk is regulatory and manufacturing execution, not a likely patent blocking position.
An applicant seeking approval for a conventional equivalent would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant regulatory work would focus on pharmaceutical equivalence, bioequivalence, manufacturing controls, stability, labeling, and facility compliance.[4]
When did spironolactone/hydrochlorothiazide lose exclusivity?
The combination lost meaningful market exclusivity decades ago. Aldactazide was introduced in the early era of modern antihypertensive therapy, and generic competition has existed for many years.
The key commercial milestones are:
| Period |
Event |
| 1960s |
Aldactazide introduced as a fixed-dose diuretic combination |
| Later decades |
Generic equivalents become available |
| Post-generic period |
Price competition increases and branded differentiation weakens |
| Current market |
Mature generic supply with limited patent-based barriers |
Because the product is old, its commercial life is no longer governed by a single future patent expiration date. The relevant issue is the availability and reliability of current generic suppliers.
Are there Paragraph IV challenges to this product?
Paragraph IV litigation is not a major current market issue for the conventional product. Paragraph IV certifications are most valuable when an ANDA applicant seeks approval before expiration of an active Orange Book patent. For an old fixed-dose combination whose primary patent estate has expired, a Paragraph IV strategy has limited practical relevance.
Potential disputes could still arise over:
- A newly listed formulation patent
- A manufacturing-process patent
- A narrow method-of-use patent
- Labeling differences
- Bioequivalence or inactive-ingredient issues
- Patent listing disputes involving a legacy NDA
Those issues would be product-specific. They do not create a broad barrier to generic spironolactone/hydrochlorothiazide tablets.
Which companies compete in the market?
Competition is fragmented among generic pharmaceutical companies. Historical and current suppliers of spironolactone, hydrochlorothiazide, and related fixed-dose products have included large generic manufacturers, specialty suppliers, and contract manufacturers. Supplier participation can vary by strength, dosage form, and market.
The most relevant competitive groups are:
Large generic manufacturers
Large companies can compete through national distribution, lower manufacturing costs, and broad formularies. Their product-level revenues are generally aggregated with other generic medicines.
Specialty generic suppliers
Smaller companies may target limited strengths, institutional customers, or markets where larger suppliers have discontinued products. Their commercial risk is higher because a single manufacturing interruption can materially affect supply.
Component-drug manufacturers
Suppliers of standalone spironolactone and hydrochlorothiazide are indirect competitors. Their products can replace the fixed-dose combination and limit pricing power.
Alternative combination manufacturers
Other diuretic and antihypertensive combinations compete for the same clinical use cases. Important alternatives include triamterene/hydrochlorothiazide, amiloride/hydrochlorothiazide, and combinations involving angiotensin receptor blockers or ACE inhibitors.
How does it compare with competing diuretic combinations?
| Product |
Main advantage |
Main limitation |
Commercial position |
| Spironolactone/HCTZ |
Combines aldosterone blockade with thiazide diuresis |
Hyperkalemia, electrolyte monitoring, dose rigidity |
Mature niche generic |
| Triamterene/HCTZ |
Potassium-sparing effect with established hypertension use |
Renal and electrolyte risks |
Established generic alternative |
| Amiloride/HCTZ |
Potassium-sparing diuretic combination |
Lower commercial scale |
Smaller generic segment |
| Separate spironolactone plus HCTZ |
Flexible dose adjustment |
More tablets and prescriptions |
Clinically flexible substitute |
| ARB/HCTZ combinations |
Strong hypertension positioning and broad guideline use |
Less useful when aldosterone antagonism is specifically required |
More commercially important |
| Eplerenone plus thiazide |
More selective mineralocorticoid receptor blockade |
Higher cost and separate dosing |
Niche alternative |
The fixed-dose combination’s principal disadvantage is dose inflexibility. Spironolactone and hydrochlorothiazide are often titrated separately, particularly in patients with renal impairment, hyperkalemia risk, heart failure, or changing volume status.
What formulation and manufacturing IP remains relevant?
Conventional tablets have low IP differentiation. A manufacturer seeking defensible value would need to focus on technical attributes such as:
- Improved dissolution or stability
- Reduced degradation of spironolactone
- Modified-release delivery
- Novel packaging that limits moisture or light exposure
- Taste or swallowability improvements
- Pediatric or geriatric dosage forms
- A validated manufacturing process with lower impurity formation
These approaches would require meaningful technical and regulatory support. A minor excipient change would not create durable market exclusivity unless it produced a patentable and clinically or commercially relevant result.
Manufacturing remains more important than patent ownership. Spironolactone is a steroidal compound, and consistent control of impurities, assay, dissolution, and stability is essential. Hydrochlorothiazide adds a second API and increases the need for blend uniformity and dose-control validation.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. The principal business risks are:
- Further price erosion
- Supplier consolidation
- API shortages
- FDA manufacturing observations
- Product discontinuation in low-volume strengths
- Retail substitution with separate component drugs
- Hospital and payer preference for alternative diuretic combinations
- Reduced prescribing of fixed-dose products in patients requiring individualized titration
The principal upside scenario is supply contraction. If several manufacturers exit, remaining suppliers may experience improved utilization and temporary price expansion. That opportunity is usually vulnerable to new entrants and renewed production by existing competitors.
What litigation and settlement issues affect the product?
No major current patent settlement framework is associated with conventional spironolactone/hydrochlorothiazide tablets. The product predates the modern branded-generic litigation cycle that has shaped newer pharmaceutical launches.
Potential disputes would more likely involve:
- ANDA approval or filing deficiencies
- Product liability
- Current Good Manufacturing Practice compliance
- False or misleading labeling
- Distribution contracts
- Antitrust issues involving generic supply or pricing
Those risks are separate from the expired patent estate and should be analyzed through current FDA enforcement records, court dockets, and manufacturer disclosures.
What is the geographic coverage of the market?
The product is commercially relevant in the United States and other markets with established generic prescribing. Geographic performance varies because:
- Some countries use the separate ingredients more often.
- Fixed-dose combinations may have different registration status.
- Pricing systems differ materially.
- Public procurement can dominate sales in some markets.
- Local manufacturers may supply the product under different names.
- Spironolactone prescribing patterns differ by heart failure and hypertension guidelines.
The United States has the clearest regulatory structure through NDA and ANDA records. European and other international markets require separate review of national or regional marketing authorizations, pricing, and reimbursement.
Key Takeaways
- Spironolactone/hydrochlorothiazide is a mature generic fixed-dose combination.
- Aldactazide’s original patent and exclusivity position has expired.
- No biosimilar risk exists because the product is a small molecule.
- Current value is based on reliable manufacturing and distribution, not patent protection.
- Public companies rarely disclose product-level revenue for the combination.
- Revenue is likely stable to declining in ordinary conditions, with temporary upside from supply shortages.
- Separate spironolactone and hydrochlorothiazide prescriptions are major substitutes.
- Dose inflexibility limits use in heart failure, renal disease, and complex electrolyte management.
- Paragraph IV litigation is not a central current risk for conventional tablets.
- The most important diligence areas are supplier count, FDA compliance, API sourcing, strength availability, and reimbursement access.
FAQs
Is spironolactone/hydrochlorothiazide still commercially available?
Yes. Generic tablets remain the principal commercial form, although availability can differ by strength, manufacturer, pharmacy, and country.
Does Aldactazide still have meaningful brand value?
Limited brand value remains. The market is primarily generic, and prescribers can substitute separate spironolactone and hydrochlorothiazide products.
Can a company obtain a new patent on spironolactone/hydrochlorothiazide?
Yes, but only for a qualifying novel formulation, manufacturing process, dosage form, or method of use. A new patent would not generally cover the old conventional tablet broadly.
Is spironolactone/hydrochlorothiazide a high-growth pharmaceutical product?
No. It is a low-growth or mature product. Growth is more likely to result from supply disruption or market-share shifts than from expanding clinical demand.
What is the main investment risk for a generic manufacturer?
The main risks are price erosion, supplier competition, API disruption, manufacturing compliance issues, and substitution by separate component drugs or newer antihypertensive combinations.
References
- U.S. Food and Drug Administration. (n.d.). Aldactazide prescribing information. FDA Drugs@FDA.
- U.S. Food and Drug Administration. (n.d.). Spironolactone prescribing information. FDA Drugs@FDA.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generic drug approval process. FDA.
